Efgartigimod: Clinical Development of a Novel FcRn Antagonist in the Treatment of Autoimmune Diseases

Main Article Content

Olga Ostrovskaya
argenx, Ghent, Belgium

Magdalena Sips
argenx, Ghent, Belgium

Peter Ulrichts
argenx, Ghent, Belgium

Lance Trainor
argenx, Ghent, Belgium

Peter Verheesen
argenx, Ghent, Belgium

Ivaylo Stoykov
argenx, Ghent, Belgium

Keywords

pemphigus, immunoglobulins, autoimmune, efgartigimod, FcRn, Dsg-1, Dsg-3, IgG, bullous pemphigoid, BP-180, BP-230

References

1. Sesarman A, et al. Cell Mol Life Sci. 2010;67:2533–50.

2. Ulrichts P, et al. J Clin Invest. 2018;128:4372–86.

3. Vaccaro C, et al. Nat Biotech. 2005;23:1283–88.

4. Newland AC, et al. Am J Hematol. 2020;95:178–87.

5. Goebeler M, et al. Br J Dermatol. 2022;10:1111.

6. Howard JF Jr, et al. Lancet Neurol. 2021;20:526–36.

7. argenx, Inc. (March 22, 2022). Topline Results: ADAPT-SC Bridging Study in gMG.

8. argenx, Inc. (May 5, 2022). Topline Results: ADVANCE study in ITP.

9. Schmidt E, et al. Lancet. 2019;394:882.

10. Amagai M, et al. J Am Acad Dermatol. 1999;40:167–70.

11. Kridin K, et al. Front Med (Laussane). 2018;5:220.

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.193

Article Details

How to Cite
Ostrovskaya, O., Sips, M., Ulrichts, P., Trainor, L., Verheesen, P., & Stoykov, I. (2023). Efgartigimod: Clinical Development of a Novel FcRn Antagonist in the Treatment of Autoimmune Diseases. SKIN The Journal of Cutaneous Medicine, 7(2), s193. https://doi.org/10.25251/skin.7.supp.193
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Dermatopharmacology
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)